Research Analysts Offer Predictions for RARE FY2025 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Ultragenyx Pharmaceutical in a report released on Monday, July 14th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will post earnings of ($5.15) per share for the year, down from their prior forecast of ($5.08). The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. Cantor Fitzgerald also issued estimates for Ultragenyx Pharmaceutical’s FY2026 earnings at ($3.00) EPS.

A number of other equities research analysts have also recently weighed in on the company. William Blair assumed coverage on Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They issued an “outperform” rating and a $65.00 price objective for the company. Morgan Stanley dropped their price objective on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday. Wells Fargo & Company dropped their price objective on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating for the company in a research note on Thursday, July 10th. Guggenheim reaffirmed a “buy” rating and issued a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. Finally, Wedbush dropped their price objective on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating for the company in a research note on Monday. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $83.64.

Ultragenyx Pharmaceutical Trading Up 0.4%

Shares of NASDAQ RARE opened at $27.31 on Wednesday. Ultragenyx Pharmaceutical has a twelve month low of $26.85 and a twelve month high of $60.37. The stock has a fifty day simple moving average of $36.00 and a 200-day simple moving average of $38.46. The stock has a market capitalization of $2.58 billion, a PE ratio of -4.64 and a beta of 0.26.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 93.04% and a negative return on equity of 186.49%. The business had revenue of $139.29 million during the quarter, compared to analysts’ expectations of $145.98 million. During the same quarter in the prior year, the firm earned ($2.03) EPS. Ultragenyx Pharmaceutical’s revenue for the quarter was up 28.0% compared to the same quarter last year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of RARE. GAMMA Investing LLC boosted its position in shares of Ultragenyx Pharmaceutical by 76.2% during the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 323 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of Ultragenyx Pharmaceutical by 1,061.9% during the 2nd quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 669 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth about $35,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter worth about $57,000. Finally, Headlands Technologies LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter worth about $59,000. 97.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the business’s stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the completion of the transaction, the director directly owned 15,344 shares of the company’s stock, valued at $573,712.16. The trade was a 13.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last ninety days, insiders sold 3,167 shares of company stock worth $118,824. Insiders own 5.50% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.